open access

Vol 10, No 4 (2014)
Review paper
Published online: 2014-08-29
Get Citation

EGFR tyrosine kinase inhibitors in the first-line or second-line treatment of patients with EGFR gene activating mutation

Magdalena Knetki-Wróblewska, Adam Płużański, Maciej Krzakowski
Onkol. Prak. Klin 2014;10(4):184-191.

open access

Vol 10, No 4 (2014)
REVIEW ARTICLES
Published online: 2014-08-29

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) are a new group of agents for non-small-cel lung cancer patients. Identification of the predictive value of activating EGFR gene mutations allowed selection of patients likely to achieve true clinical benefit. TKI-EGFR may produce objective responses in more than 60% of patients and prolong progression-free survival to 10 months in mutation-positive patients. No improvement of overall survival was shown in randomized trials. Similar benefits were observed in patients within second-line treatment. No data are available for superiority of TKI-chemotherapy sequence over the reverse use of chemotherapy and TKI. It is suggested, that TKI-EGFR should be first-line treatment for mutation-positive patients, because of PFS and ORR benefit, better tolerance of treatment and quality of life improvement. According to current guidelines, mutation-positive patients should receive TKI-EGFR with a probability of overall survival in a range of 20 months in majority of patients. We aimed to review the literature on the use of TKI-EGFR as first-line and second-line treatment for mutation-positive non-small-cell lung cancer patients.

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) are a new group of agents for non-small-cel lung cancer patients. Identification of the predictive value of activating EGFR gene mutations allowed selection of patients likely to achieve true clinical benefit. TKI-EGFR may produce objective responses in more than 60% of patients and prolong progression-free survival to 10 months in mutation-positive patients. No improvement of overall survival was shown in randomized trials. Similar benefits were observed in patients within second-line treatment. No data are available for superiority of TKI-chemotherapy sequence over the reverse use of chemotherapy and TKI. It is suggested, that TKI-EGFR should be first-line treatment for mutation-positive patients, because of PFS and ORR benefit, better tolerance of treatment and quality of life improvement. According to current guidelines, mutation-positive patients should receive TKI-EGFR with a probability of overall survival in a range of 20 months in majority of patients. We aimed to review the literature on the use of TKI-EGFR as first-line and second-line treatment for mutation-positive non-small-cell lung cancer patients.

Get Citation

Keywords

non-small-cell lung cancer, epidermal growth factor receptor tyrosine kinase inhibitors, chemotherapy

About this article
Title

EGFR tyrosine kinase inhibitors in the first-line or second-line treatment of patients with EGFR gene activating mutation

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 4 (2014)

Article type

Review paper

Pages

184-191

Published online

2014-08-29

Bibliographic record

Onkol. Prak. Klin 2014;10(4):184-191.

Keywords

non-small-cell lung cancer
epidermal growth factor receptor tyrosine kinase inhibitors
chemotherapy

Authors

Magdalena Knetki-Wróblewska
Adam Płużański
Maciej Krzakowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl